Amgen (AMGN)
(Delayed Data from NSDQ)
$319.66 USD
+2.18 (0.69%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$319.66 USD
+2.18 (0.69%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Zacks News
Amgen (AMGN) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
Amgen (AMGN) concluded the recent trading session at $319.66, signifying a +0.69% move from its prior day's close.
Why Amgen (AMGN) Dipped More Than Broader Market Today
by Zacks Equity Research
In the most recent trading session, Amgen (AMGN) closed at $317.48, indicating a -0.7% shift from the previous trading day.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Amgen (AMGN) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Amgen (AMGN) closed at $322.67 in the latest trading session, marking a +1.12% move from the prior day.
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why
by Zacks Equity Research
Though Amgen reported encouraging results on two immunology drugs, Wall Street expresses skepticism as the data fell short when compared to existing treatments.
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
by Zacks Equity Research
A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.
Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Amgen (AMGN) stood at $335.61, denoting a -0.52% change from the preceding trading day.
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
by Ahan Chakraborty
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
Amgen (AMGN) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Amgen (AMGN) reachead $332.80 at the closing of the latest trading day, reflecting a -0.73% change compared to its last close.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen (AMGN) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $335.26, moving +0.85% from the previous trading session.
VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints
by Zacks Equity Research
The phase III THRIVE study evaluating Viridian's veligrotug for treating active thyroid eye disease meets all primary and secondary endpoints.
Why Amgen (AMGN) Outpaced the Stock Market Today
by Zacks Equity Research
Amgen (AMGN) reachead $328.93 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
by Zacks Equity Research
TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Amgen (AMGN) Up 5.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amgen Stock Rises Almost 20% in 6 Months: Buy, Sell or Hold?
by Kinjel Shah
AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested for now.
Why the Market Dipped But Amgen (AMGN) Gained Today
by Zacks Equity Research
In the closing of the recent trading day, Amgen (AMGN) stood at $330.64, denoting a +0.04% change from the preceding trading day.
Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound
by Zacks Equity Research
LLY's single-dose vials are priced at least 50% lower than the list price of all other GLP-1 medicines for obesity.
Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday
by Zacks Equity Research
VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.
Should Invesco Large Cap Value ETF (PWV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWV
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Lilly (LLY) Up 3% on Obesity Drug Cutting Diabetes Risk
by Zacks Equity Research
Eli Lilly (LLY) reports data from a late-stage study that found that long-term treatment with Zepbound reduces the risk of progression to type 2 diabetes by 94%.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH